Starpharma Holdings Limited (SPHRY)
OTCMKTS · Delayed Price · Currency is USD
3.550
+0.750 (26.79%)
Feb 11, 2026, 2:40 PM EST
Starpharma Holdings Employees
Starpharma Holdings had 40 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
40
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$95,883
Profits / Employee
-$163,738
Market Cap
141.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 40 | 0 | - |
| Jun 30, 2024 | 40 | -5 | -11.11% |
| Jun 30, 2023 | 45 | -5 | -10.00% |
| Jun 30, 2022 | 50 | 0 | - |
| Jun 30, 2021 | 50 | 5 | 11.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
Starpharma Holdings News
- 5 months ago - ASX 200 LIVE: ASX climbs, tracking Wall Street; Starpharma inks deal with Roche Group; Reece plans share buyback; Santos receives first gas in Barossa field. - The Australian Financial Review
- 2 years ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 3 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 4 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 5 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha